Marshall Wace, LLP Selecta Biosciences Inc Transaction History

Marshall Wace, LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.15 - $1.89 $13,445 - $22,097	-11,692 Reduced 0.89%	1,298,751 $1.81 Million
Q4 2022 Feb 14, 2023	SELL	$0.96 - $1.6 $517,081 - $861,803	-538,627 Reduced 29.13%	1,310,443 $1.48 Million
Q3 2022 Nov 14, 2022	BUY	$1.33 - $2.6 $1.15 Million - $2.25 Million	866,384 Added 88.16%	1,849,070 $3.03 Million
Q2 2022 Aug 15, 2022	BUY	$0.67 - $1.4 $317,176 - $662,757	473,398 Added 92.95%	982,686 $1.29 Million
Q1 2022 May 16, 2022	SELL	$1.23 - $3.31 $1.82 Million - $4.91 Million	-1,482,300 Reduced 74.43%	509,288 $627,000
Q4 2021 Feb 14, 2022	BUY	$2.89 - $4.43 $4.88 Million - $7.47 Million	1,687,291 Added 554.49%	1,991,588 $6.49 Million
Q2 2021 Aug 13, 2021	BUY	$2.82 - $5.01 $858,117 - $1.52 Million	304,297 New	304,297 $1.27 Million
Q4 2020 Feb 16, 2021	SELL	$1.64 - $3.42 $1.68 Million - $3.5 Million	-1,023,056 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$2.18 - $2.84 $2.23 Million - $2.91 Million	1,023,056 New	1,023,056 $2.54 Million
Q4 2018 Feb 14, 2019	SELL	$2.66 - $15.93 $67,811 - $406,103	-25,493 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$12.07 - $16.0 $307,700 - $407,888	25,493 New	25,493 $396,000

4.67M

Ticker SELB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 152,712,992
Market Cap $128M
Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.